The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
There are several prognostic multigene-based tests for managing breast cancer (BC), but limited data comparing them in the same cohort. We compared the prognostic performance of the EndoPredict (EP) test (standardized for pathology laboratory) with the research-based PAM50 non-standardized qRT-PCR assay in node-positive estrogen receptor-positive (ER+) and HER2-negative (HER2−) BC patients receiving...
Als Grundlage einer individualisierten Therapie kommt der Untersuchung molekularer Biomarker eine immer größere Bedeutung zu. Beim Mammakarzinom werden derzeit standardmäßig die Hormonrezeptoren, HER2 sowie ggf. Ki67 bestimmt. In neuerer Zeit gibt es insbesondere für hormonrezeptorpositive HER2-negative Karzinome eine zusätzliche Möglichkeit der Durchführung von Genexpressionstests. Hier werden innerhalb...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.